Finally, the genome-wide DNAm alterations identified by the NSD1+/−-specific signature represent novel, powerful and highly specific targets that can be used to elucidate the molecular pathophysiology of SS and to guide the development of future targeted therapies. The gene discussed is NSD1; the disease is synovial sarcoma.